Recent Updates
Recently added Catalysts

aerosolized vancomycin or gentamicin

Phase 2

Ventilator Associated Pneumonia | Small molecule | Infectious Disease |Nektar Therapeutics|Last Updated: Nov 7, 2006

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment80
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00396578Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical VentilationPHASE2 COMPLETED 80Aug 1, 2003Sep 1, 2004Nov 7, 20061 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Ventilator associated pneumonia Systemic Antibiotic use Clinical pulmonary infection score
Secondary Endpoints
Weaning from mechanical ventilation Bacterial resistance
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
aerosolized vancomycin or gentamicinDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * be on mechanical ventilation greater than 3 days * greater than or equal to 18 years of age survival greater than 14 days * greater than 2 ccs of tracheal secretions/4 hours Exclusion Criteria: * allergy to drugs, pregnancy

Countries:United States
Unlock Eligibility Criteria